目的 对比分析阿托伐他汀和瑞舒伐他汀所致药品不良反应，为临床安全、合理选择降脂药提供参考。方法 采用回顾性分析的方法，对福州市长乐区医院2010—2019年上报的怀疑阿托伐他汀和瑞舒伐他汀所致不良反应病例报告进行对比分析。分别从患者一般情况、用药情况、累及系统-器官损害、观察指标、不良反应发生时间分布、及转归等方面进行统计分析。结果 共筛选出89例阿托伐他汀所致的不良反应报告、38例瑞舒伐他汀所致的不良反应报告。阿托伐他汀以肝胆系统损害及骨骼肌系统损害多见，瑞舒伐他汀以肝胆系统及泌尿系统损害多见；阿托伐他汀涉及系统器官的不良反应表现较多，阿托伐他汀和瑞舒伐他汀出现的LFTs>3×ULN、CK>10×ULN、SAMS的比较差异均无统计学意义。阿托伐他汀不良反应多发生在用药4～18 d，而瑞舒伐他汀多发生在5～20 d。阿托伐他汀与瑞舒伐他汀引起的不良反应大部分为严重，经采取相应措施治疗后易于好转及治愈。结论 阿托伐他汀与瑞舒伐他汀引发的不良反应临床表现有所不同，但不良反应发生时间及主要不良反应观察指标相似，临床用药中应当根据实际情况进行使用，以保障用药安全。

Objective To compare and analyze the adverse drug reactions (ADR) caused by atorvastatin and rosuvastatin, and to provide a reference for clinical safety and reasonable choice of lipid-lowering drugs. Methods A retrospective analysis method was used to compare and analyze the case reports of suspected atorvastatin and rosuvastatin reported from 2010 to 2019 in Fuzhou Changle District Hospital. Statistical analysis was conducted in terms of patients' general condition, medication situation, systemorgan damage involved, observation indexes, time distribution of adverse reactions, and outcomes, etc. Results A total of 89 ADR reports suspected to be caused by atorvastatin and 38 ADR reports suspected to be caused by rosuvastatin were screened. Atorvastatin was more common in hepatobiliary system damage and skeletal muscle system damage, rosuvastatin was more common in hepatobiliary system damage and urinary system damage. Atorvastatin involved systemic organs with more adverse reactions, and the LFTS > 3×ULN, CK > 10×ULN and SAMs between atorvastatin and rosuvastatin showed no statistical significance. The ADR of atorvastatin mostly occurred 4 — 18 days after administration, while rosuvastatin mostly occurred 5 — 20 days after administration. Most of the ADRs caused by atorvastatin and rosuvastatin were severe, which were easy to improve and cure after treatment with appropriate measures. Conclusion The clinical manifestations of ADR caused by atorvastatin and rosuvastatin are different, but the occurrence time of ADR and the main adverse reaction observation indicators are similar. Clinical medication should be used according to actual conditions to ensure the safety of medication.

R972